Could a Cure for Alzheimer’s be Invented in the Triangle? Absolutely.

By The Editors of Talking Trials,

Currently, the estimated annual cost of nine common neurological diseases totals to $800 billion, predictably increasing as the elderly population doubles by 2050. More specifically, there is a catastrophic unmet need in Alzheimer’s disease treatment, prevention and clinical research. In a recent segment with WRAL News’ Health Team with Dr. Allen Mask, Worldwide Clinical Trials’ chief operating officer, Peter Benton, discusses Worldwide’s uncommon approach to fighting against neurodegenerative diseases through its recent partnership with Datavant.

Read More

Secure, Real-World Data Drives Enhanced Insights for Neurodegenerative Disease Trials

By Dr. Natalia Drosopoulou, Executive Director of Project Management and Franchise Area Lead in Neuroscience, Worldwide Clinical Trials,

Neurodegenerative disease clinical trials are challenging, but they don’t have to be. Optimizing clinical trial patient recruitment and outcomes with external data sets can open new opportunities for pharma and biotech companies seeking to enhance their clinical trials in areas such as compliance, adherence, enrollment, safety, and even efficacy.

Read More